Therapeutic Formulations of Repurposed Drugs against COVID-19

Dear Colleagues,

Since the beginning of the COVID-19 pandemic, almost 3 million lives have been taken by SARS-CoV-2 worldwide, and many more are expected until its end.

Multiple advances in the pharmacological treatment of severe cases have been made over the last year, in particular, dexamethasone to control inflammatory response and several repurposed drugs as antivirals. In the latter, very promising results have been achieved at several stages of the pandemic, as the pipeline for the development of new drugs is particularly lengthy, lasting at least 10 years. Hence, novel formulations of old drugs that enable enhanced pharmacokinetics and pharmacodynamics to efficiently manage and treat severe COVID-19 are ubiquitously required.

In this Special Issue, we invite academic and industrial research partners to contribute with innovative works on new therapeutic formulations of repurposed drugs against SARS-CoV-2, which may include nanocarriers, nanoreactors, microemulsions, microspheres, dry powders, co-crystals, organic salts, ionic liquids, eutectic systems, amorphous solid dispersions, among many others. In vitro, in vivo and in silico studies regarding alternative drug administration modes (pulmonary, transdermal, percutaneous) of such drugs are also welcomed.

Dr. Luis Cobra Branco
Dr. Miguel Santos
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.